Get the Stockscreener App
95.76
0.90%
0.85
After Hours:
95.05
-0.71
-0.74%
Dianthus Therapeutics Inc stock is traded at $95.76, with a volume of 709.39K.
It is up +0.90% in the last 24 hours and up +22.99% over the past month.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
See More
Previous Close:
$94.91
Open:
$94.88
24h Volume:
709.39K
Relative Volume:
0.67
Market Cap:
$5.21B
Revenue:
$2.04M
Net Income/Loss:
$-162.34M
P/E Ratio:
-23.28
EPS:
-4.1129
Net Cash Flow:
$-129.27M
1W Performance:
+9.47%
1M Performance:
+22.99%
6M Performance:
+164.53%
1Y Performance:
+398.49%
1-Day Range:
$93.16
$96.00
1-Week Range:
$87.08
$96.05
52-Week Range:
$16.64
$96.05
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
95.76 | 5.17B | 2.04M | -162.34M | -129.27M | -4.1129 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-10-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics CFO Sells $9.5 Million in Stock - AOL.com
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year HighShould You Buy? - MarketBeat
Dianthus Therapeutics EVP Sells $10M in Shares - National Today
SG Americas Securities LLC Invests $765,000 in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
DNTH SEC FilingsDianthus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares - MarketBeat
Ryan Savitz, Dianthus Therapeutics CFO, sells $738k in DNTH stock - Investing.com Canada
Dianthus Therapeutics Insider Sold Shares Worth $738,844, According to a Recent SEC Filing - marketscreener.com
Dianthus (NASDAQ: DNTH) CFO exercises options, sells 8,224 shares under 10b5-1 plan - Stock Titan
Dianthus Therapeutics Upgraded to Strong Buy at Wolfe Research - National Today
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded by Wolfe Research to "Strong-Buy" Rating - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 90.2 USD By Investing.com - Investing.com Australia
Ryan Savitz files Form 144 to sell 8,224 shares (NASDAQ: DNTH) - Stock Titan
Dianthus Therapeutics (DNTH) details 2026 director, pay and auditor votes - Stock Titan
Dianthus Therapeutics stock hits 52-week high at 90.2 USD - Investing.com
Wolfe Research Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month HighTime to Buy? - MarketBeat
Can Dianthus Therapeutics Inc expand into new marketsEarnings Growth Report & Low Risk High Reward Ideas - baoquankhu1.vn
Dianthus Therapeutics, Inc.Common Stock (DNTH) Stock Price, News, Quote & History - FinancialContent
Dianthus Therapeutics Announces Inducement Grants - National Today
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dianthus Therapeutics CFO Sells $9.5 Million in Stock - The Motley Fool
JPMorgan Chase & Co. Has $2.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus gives 8 new employees stock options at $84.56 a share - Stock Titan
Aug Momentum: Can Dianthus Therapeutics Inc expand into new markets2026 Retail Activity & AI Enhanced Trading Alerts - baoquankhu1.vn
Dianthus Therapeutics, Inc. (DNTH) stock price, news, quote and history - Yahoo Finance UK
A Look At Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains - Sahm
Wedbush keeps outperform on Dianthus Therapeutics, Inc. (DNTH), highlights potential of Claseprubart in CIDP - MSN
Dianthus Therapeutics EVP Sells Over $9 Million in Shares - National Today
How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,492,461.00 in Stock - MarketBeat
Dianthus Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Wells Fargo Remains a Buy on Dianthus Therapeutics (DNTH) - The Globe and Mail
Dianthus Therapeutics(DNTH.US) Officer Sells US$9.49 Million in Common Stock - Moomoo
Dianthus Therapeutics stock hits 52-week high at 88.35 USD By Investing.com - Investing.com Australia
Dianthus therapeutics director Soteropoulos sells $47985 in stock By Investing.com - Investing.com Australia
Dianthus therapeutics director Soteropoulos sells $47985 in stock - Investing.com
Savitz of Dianthus sold $9.5m in DNTH stock - Investing.com UK
Savitz of Dianthus sold $9.5m in DNTH stock By Investing.com - Investing.com South Africa
Dianthus Therapeutics Insider Sold Shares Worth $9,492,596, According to a Recent SEC Filing - marketscreener.com
Dianthus Therapeutics (DNTH) CFO exercises options, sells 114,367 shares - Stock Titan
Dianthus Therapeutics (DNTH) director exercises options then sells 599 shares - Stock Titan
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics stock hits 52-week high at 88.35 USD - Investing.com
Dianthus rises as FDA agrees with proposed changes to lead program - MSN
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):